A pharmacological overview of lamotrigine for the treatment of epilepsy

Expert Review of Clinical Pharmacology

Volumn 9, Issue 12, 2016, Pages 1533-1546

  Yasam, Venkata Ramesh ^a   Jakki, Satya Lavanya ^a   Senthil, V ^a   Eswaramoorthy, M ^b   Shanmuganathan, S ^c   Arjunan, K ^d   Nanjan, M ^a  

^a JSS COLLEGE OF PHARMACY   (India)

^b JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^c SRI RAMACHANDRA UNIVERSITY   (India)

^d PSG COLLEGE OF PHARMACY   (India)

Author keywords

Epilepsy; lamotrigine; pharmacokinetics; sodium channel blocker; women

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; TRIAZINE DERIVATIVE;

CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); EPILEPSY; HUMAN;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; EPILEPSY; HUMANS; MOLECULAR STRUCTURE; TRIAZINES;

EID: 84996432109     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2016.1254041     Document Type: Article

References (123)

1. Hommes OR, Obbens EA., The epileptogenic action of sodium folate in the rat. J Neurol Sci. 1972;20:269–272.
2. Reynolds EH, Milner G, Matthews PM, et al. Anticonvulsant therapy, megaloblastic hematopoiesis and folic acid metabolism. Q J Med. 1966;35:521–537.
3. Oluwaseun E, Imti C, Helen MS. Safety of lamotrigine in paediatrics:a systematic review. BMJ Open. 2015;5:e007711.
4. Markus R, Sarah R, Manuela P, et al. Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs:time to screen? Neuropediatrics. 2014;45(4):226–233.
5. Schmidt D, Ried S, Rapp P. Add-on treatment with lamictal for intractable partial epilepsy:a placebo-controlled crossover trial. Epilepsia. 1993;34(Suppl. 2):66.
6. Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2016;22(6):CD001909.
7. Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology. 2007;69:1610–1618.
8. Biton V, DiMemmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav. 2010;19:352–458.
9. Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge-eating disorder with obesity:a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol. 2009;24:150–158.
10. Lee WT, Shen YZ, Chang C. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid:evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience. 2000;95(1):89–95.
11. Brenner MG, Buescher ES. Breastfeeding:a clinical imperative. J Womens Health (Larchmt). 2011;20:1767–1773.
12. Lamictal™ Product Info. NC, USA:GlaxoSmithKline, Research Triangle Park; 2000.
13. Lamictal™ full prescribing information. NC, USA:GlaxoSmithKline, Research Triangle Park; 2011.
14. Cocito L, Maffini M, Loeb C. Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Research. 1994;19:123–127.
15. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345:476–479.
16. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy:a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002;43(9):993–1000.
17. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy:an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.
18. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy:Clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70:2130–2136.
19. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs:an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609–617.
20. Rosenow F, Schade Brittinger C, Burchardi N, et al. The LaLiMo Trial:lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsydan open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012. doi:10.1136/jnnp-2011-301999
21. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study):a prospective observational study. Lancet Neurol. 2013;12:244–252.
22. Yasumoto S, Shimizu M, Sato K, et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children:a multi-center, uncontrolled, open-label study. Brain & Development. 2015. doi:10.1016/j.braindev.2015.10.007
23. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology. 1993;43(11):2284.
24. Motte J, Trevathan E, Arvidsson JF. Lamotrigine for generalised seizures associated with the lennox-gastaut syndrome. N Engl J Med. 1997;337:12–1807.
25. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, lamotrigine in treatment-resistant crossover study of generalised epilepsy. Epilepsia. 1998;39(12):1329–1333.
26. Duchowny M, Pellock JM, Graf WD, et al. A placebo controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology. 1999;53(8):1724–1731.
27. Biton V, Sackellares JC, Vuong A, et al. Double blind, placebo controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology. 2005;65(11):1737–1743.• A nice article giving an insight into lamotrigine and its action on sodium channels.
28. Veiby G, Daltveit AK, Engelsen BA, et al. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579–588.
29. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):803–813.
30. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy:updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatr. 2014;85(9):1029–1034.
31. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy:results from the UK and Ireland Epilepsy and Pregnancy Registers. Neurology. 2013;80(4):400–405.
32. Hunt S, Russell A, Smithson WH, et al. UK Epilepsy and Pregnancy Register, topiramate in pregnancy:preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71(4):272–276.
33. Herna´ndez-Dı´az S, Smith CR, Shen A, et al. North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–1699.
34. Vajda FJ, Hitchcock AA, Graham J, et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia. 2010;51(5):805–810.
35. Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology. 2011;76:1817–1823.
36. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel antiepileptic drug:II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27:490–497.
37. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 1992;13:107–112.
38. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res. 1993;612:190–199.
39. Stefani A, Spadoni F, Siniscalchi A, et al. Lamotrigine inhibits Ca2+ currents in cortical neurons:functional implications. Eur J Pharmacol. 1996;307:113–116.
40. Lamb RJ. Miller AA. Effect of lamotrigine and some known anticonvulsant drugs on visually-evoked after-discharge in the conscious rat. Br J Pharmacol. 1985. p. 86:765 (Abstract).
41. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin and topiramate against human absence seizures. Epilepsia. 1997;38(4):408–414.
42. Wheatley PL, Miller AA. Effects of lamotrigine on electrically-induced after discharge duration in anaesthetized rat, dog, and marmoset. Epilepsia. 1989;30:34–40.
43. Ramsey RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine in patients with epilepsy. Epilepsy Res. 1991;10:191–200.•• Study dedicated to establish pharmacokinetics and safety of lamotrigine.
44. Parsons DN, Dickins M, Morley TJ. Lamotrigine:absorption, distribution, and excretion. In:Levy RH, Mattson RH, Meldrum BS, Editors. Antiepileptic Drugs. 4th ed. NY, USA:Raven Press; 1995. p. 877–881.
45. Martin JB. Lamotrigine–an Update. Can J Neurol Sci. 1996;23(Suppl 2):S6–S9.
46. Hale TW., Medications and mothers’ milk. 13th ed. Plano (TX):Hale Publishing; 2008. p. 532.
47. Lamotrigine. Available from:http://www.drugbank.ca/drugs/DB00555 [cited 2016 Sep 07].
48. Doig MV, Clare RA. Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr. 1991;554:181–189.
49. Yuen AWC, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992;33:511–513.
50. Yuen AWC. Lamotrigine:interactions with other drugs. In:Levy RH, Mattson RH, Meldrum BS, Editors. Antiepileptic Drugs. 4th ed. NY, USA:Raven Press; 1995. p. 883–887.
51. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind cross-over trial of Lamictal (lamotrigine) as add-on therapy in intractable epilepsy. Epilepsy Res. 1989;4:222–229.
52. Jawad S, Richens A, Goodwin G, et al. Controlled trial of Lamictal (lamotrigine) for refractory partial seizures. Epilepsia. 1989;30:356–363.
53. Sander J, Patsalos PN, Oxley JR, et al. A randomised double-blind placebo controlled add-on trial of Lamictal in patients with severe epilepsy. Epilepsy Res. 1990;6:221–226.
54. Loiseau P, Yuen AWC, Douche B, et al. A randomised double-blind placebocontrolled cross-over add-on trial of Lamictal in patients with treatmentresistant partial seizures. Epilepsy Res. 1990;7:136–145.
55. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind placebo-controlled cross-over study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry. 1993;56:448–453.
56. Johannessen LC, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119–140.•• A good study focusing on second- and third-generation antiepileptic drug interactions.
57. Contin M, Albani F, Ambrosetto G, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia. 2006;47:1573–1575.
58. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism:evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484–489.
59. Odishaw J, Chen C. Effects of steadystate bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy. 2000;20:1448–1453.
60. Depot M, Powell JR, Messenheimer JA, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther. 1990;48:346–355.
61. Stolarek I, Blacklaw J, Forrest G, et al. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry. 1994;57:921–924.
62. Wolf P. Lamotrigine:preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy. 1992;5:73–79.
63. Pisani F, Gallito G, Di Perri R. Could lamotrigine be useful in status epilepticus? A case report. J Neurol Neurosurg Psychiatry. 1991;54:845–846.• A study describing lamotrigine and its use in status epilepticus.
64. Brodie MJ. Lamotrigine versus other antiepileptic drugs:a star rating system is born. Epilepsia. 1994;35(suppl 5):S41–S46.
65. Holdish T, Whiteman P, Orme M, et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia. 1991;32(Suppl. 5):173(Abstract).
66. Doodipala SR. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol. 2010;3(2):183–192.
67. Yuen AWC, Bihari DJ. Multiorgan failure and disseminated intravascular coagulation in severe convulsive seizures. Lancet. 1992;340:618.
68. Tavernor SJ, Wong ICK, Newton R, et al. Rechallenge with lamotrigine after initial rash. Seizure. 1995;4:67–71.
69. Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. Bmj. 1995;310(6978):504.
70. Jawad S, Oxley J, Yuen WC, et al. The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. Br J Clin Pharmacol. 1986;22:191–193.
71. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures:a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia. 1994;35:113–121.
72. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34:312–322.
73. Besag FM, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr. 1995;127:991–997.
74. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol. 1997;12:S29–37.
75. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997;337:1807–1812.
76. Timmings PL, Richens A. Lamotrigine in primary generalised epilepsy. Lancet. 1992;339:1300–1301.
77. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol. 1992;32:305–307.
78. Binnie CD, Van Emde Boas W, Kasteleijn-Nolste-Trenite DG, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia. 1986;27:248–254.
79. Boas J, Cooke EA, Yuen WAC. Controlled trial of lamotrigine (Lamictal) for the treatment-resistant partial epilepsy. Epilepsia. 1995;35:S113.
80. Brodie MJ, Anhut H, Murray G, et al. Gabapentin versus lamotrigine monotherapy:a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002;43(9):993–1000.
81. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy:an unblinded randomised controlled trial. Lancet. 2007;369:1016–1026.
82. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy:an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.
83. Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56:1006–1019.
84. European Medicines Agency. Assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. [cited 2016 Sep 07]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500177352.pdf
85. Tomson T, Dina B, Emilio P. Valproic acid after five decades of use in epilepsy:time to reconsider the indications of a time-honoured drug. [Internet]. Lancet Neurol. 2015.doi:10.1016/S1474-4422(15)00314-2
86. Wechsler RT, Leroy R, Van CA. Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. Epilepsy Res. 2014;108(6):1128–1136.
87. Akshanth RP, Rory PR, Richard CB, et al. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients:use of stable isotope methodology. J Clin Pharmacol. 2015;55(10):1101–1108.
88. French JA, Temkin N, Shneker BF, et al. Lamotrigine XR conversion to monotherapy:first study using a historical control group. Neurotherapeutics. 2012;9:176–184.
89. Victor B, Bassel FS, Dean N, et al. Long-term tolerability and safety of lamotrigine extended-release:pooled analysis of three clinical trials. Clin Drug Investig. 2013;33:359–364.
90. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in the treatment of 120 children with epilepsy. Epilepsia. 1994;35(2):359–367.
91. Besag FMC. Lamotrigine:paediatric experience. In:Richens A, editor. Clinical update on lamotrigine:a novel antiepileptic agent. International Clinical Practice Series. Tunbridge Wells:Wells Medical; 1992. p. 53–60.
92. Ferrie CD, Robinson RO, Knott C, et al. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand. 1995;91(3):200–202.
93. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40(7):973–979.
94. Binnie C. An overview:efficacy of lamotrigine. In:Richens A, editor. Clinical update on lamotrigine:a novel anti-epileptic agent. International Clinical Practice Series. Tunbridge Wells:wells Medical; 1992. p. 81–87.
95. Ertl J, Hapfelmeier J, Peckmann T, et al. Guideline conform initial monotherapy increases in patients with focal epilepsy:a population based study on German health insurance data. Seizure. 2016;41:9–15.
96. Morris G, Schimschock J, Vuong A, et al. Broad spectrum activity of lamotrigine monotherapy in patients with juvenile myoclonic epilepsy. Epilepsia. 2000;41(Suppl. 7):90.
97. Kivity S, Rechtman E. Lamotrigine therapy in patients with juvenile myoclonic epilepsy and valproate-related progressive weight gain. Epilepsia. 2001;42(Suppl. 4):41.
98. Mandelbaum DE, Venkatasubramanian A, Kugler SL. Efficacy of lamotrigine in children with juvenile myoclonic epilepsy. Epilepsia. 1999;40(Suppl. 7):133–134.
99. Cohen AF, Ashby L, Crowley D, et al. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol. 1985;20:619–629.
100. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24:270–275.
101. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients:a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287–291.
102. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol. 2009;29:267–271.
103. Aliyev NA, Aliyev ZN. Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity:randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31:61–65.
104. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226–1229.
105. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder:a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175–181.
106. Berger SP, Winhusen TM, Somoza EC, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction. 2005;100:58–67.
107. Brodie MJ, Read CL, Gillham R, et al. Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia. 1999;40(suppl 2):94.
108. Halonen T, Nissinen J, Pitkanen A. Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. Epilepsy Res. 2001;46:205–223.• Studies dedicated to lamotrigine and its effect on status epilepticus-induced neuronal damage and memory impairment in rat.
109. Crumrine CR, Bergstrand K, Cooper AT. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke. 1997;28:2230–2237.
110. Yang Y, Shuaib A, Li Q. Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method. J Neurosci Methods. 1998;84(1–2):9–16.
111. Lander CM. Antiepileptic drugs in pregnancy and lactation. Aust Prescriber. 2008;31:70–72.
112. Vajda FJ, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs–the Australian experience. J Clin Neurosci. 2012;19:57–59.
113. Brown SW, Tomlinson LL. Anticonvulsant side-effects:a self report questionnaire for use in community surveys. Br J Clin Pract. 1982;18:147–149.
114. Gillham R, Baker G, Thompson P, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Epilepsy Res. 1996;24:47–55.
115. Bryant-Comstock L, Kane K, Moorat A. Quality of life improvement in patients treated with lamotrigine compared with valproate. Epilepsia. 1990;40(suppl 9):98.
116. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy:a double-blind comparison with phenytoin. Epilepsia. 1999;40(5):601–607.
117. Isojarvi JI, Lofgren E, Juntunen KS, et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology. 2004;62:247–253.
118. Stephen LJ, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001;42(8):1002–1006.
119. Betts T, Goodwin G, Withers RM, et al. Human safety of lamotrigine. Epilepsia. 1991;32(Suppl. 2):S17–S21.
120. Gaetano Z, Diego F, Emilio P. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–1244.
121. Vajda FJ, Angelis-Stoforidis P, Eadie MJ. Utility of plasma lamotrigine concentrations. Concept of the plasma therapeutic range for individual patients. Annual scientific meeting of European Neurological Society, Milan. J Neurol. 1999 [1999 Jun5–10];246(Suppl. 1):196.
122. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005;65:185–188.
123. Morris RG, Black AB, Harris A, et al. Lamotrigine and therapeutic drug monitoring:retrospective survey following the introduction of a routine service. Br J Clin Pharmacol. 1998;46:547–551.